Irbesartan for the prevention of atrial arrhythmias and cardiac electrical remodeling in patients with hypertension, permanent pacemakers and risk factors for developing atrial fibrillation

Trial Profile

Irbesartan for the prevention of atrial arrhythmias and cardiac electrical remodeling in patients with hypertension, permanent pacemakers and risk factors for developing atrial fibrillation

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Irbesartan (Primary)
  • Indications Supraventricular arrhythmias
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Jul 2007 The expected completion date for this trial is now 1 Jul 2007.
    • 20 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top